<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39407208</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-811X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Cell communication and signaling : CCS</Title><ISOAbbreviation>Cell Commun Signal</ISOAbbreviation></Journal><ArticleTitle>Innate immune response in COVID-19: single-cell multi-omics profile of NK lymphocytes in a clinical case series.</ArticleTitle><Pagination><StartPage>496</StartPage><MedlinePgn>496</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">496</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12964-024-01867-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) represents the biggest global health emergency in recent decades. The host immune response to SARS-CoV-2 seems to play a key role in disease pathogenesis and clinical manifestations, with Natural Killer (NK) lymphocytes being among the targets of virus-induced regulation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study performed a single-cell multi-omics analysis of transcripts and proteins of NK lymphocytes in COVID-19 patients, for the characterization of the innate immunological response to infection. NK cells were isolated from peripheral blood samples collected from adult subjects divided into 3 study groups: (1) non-infected subjects (Naïve group, n = 3), (2) post COVID-19 convalescent subjects (Healed group, n = 3) and (3) patients that were vaccinated against SARS-CoV-2 (Vaccine group, n = 3). Cells were then analysed by the BD Rhapsody System for the single-cell multi-omics investigation of transcriptome and membrane proteins.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The bioinformatic analysis identified 5 cell clusters which differentially expressed gene/protein markers, defining NK cell subsets as "Active NK cells" and "Mature NK cells". Calculating the relative proportion of each cluster within patient groups, more than 40% of the Naïve group cell population was found to belong to Mature NKs, whereas more than 75% of the Vaccine group cell population belonged to the cluster of Active NKs. Regarding the Healed group, it seemed to show intermediate phenotype between Active and Mature NK cells. Differential expression of specific genes, proteins and signaling pathways was detected comparing the profile of the 3 experimental groups, revealing a more activated NK cell phenotype in vaccinated patients versus recovered individuals.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present study detected differential expression of NK cell markers in relation to SARS-CoV-2 infection and vaccine administration, suggesting the possibility to identify key molecular targets for clinical-diagnostic use of the individual response to viral infection and/or re-infection.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barbon</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Human Anatomy, Department of Neuroscience, University of Padova, Via Gabelli 65, 35121, Padova, Italy. silvia.barbon@unipd.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Foundation for Biology and Regenerative Medicine, Tissue Engineering and Signaling - T.E.S. Onlus, Padova, Italy. silvia.barbon@unipd.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armellin</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Complex Operative Unit of Transfusion Medicine - Marca Trevigiana Local Unit of Health and Social Services 2, Treviso Hospital, Piazzale dell'Ospedale 1, 31100, Treviso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passerini</LastName><ForeName>Verena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Foundation for Biology and Regenerative Medicine, Tissue Engineering and Signaling - T.E.S. Onlus, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Angeli</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Complex Operative Unit of Transfusion Medicine - Marca Trevigiana Local Unit of Health and Social Services 2, Treviso Hospital, Piazzale dell'Ospedale 1, 31100, Treviso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Primerano</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Complex Operative Unit of Transfusion Medicine - Marca Trevigiana Local Unit of Health and Social Services 2, Treviso Hospital, Piazzale dell'Ospedale 1, 31100, Treviso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Pup</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Complex Operative Unit of Transfusion Medicine - Marca Trevigiana Local Unit of Health and Social Services 2, Treviso Hospital, Piazzale dell'Ospedale 1, 31100, Treviso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durante</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Complex Operative Unit of Transfusion Medicine - Marca Trevigiana Local Unit of Health and Social Services 2, Treviso Hospital, Piazzale dell'Ospedale 1, 31100, Treviso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macchi</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Section of Human Anatomy, Department of Neuroscience, University of Padova, Via Gabelli 65, 35121, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Caro</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Section of Human Anatomy, Department of Neuroscience, University of Padova, Via Gabelli 65, 35121, Padova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Foundation for Biology and Regenerative Medicine, Tissue Engineering and Signaling - T.E.S. Onlus, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parnigotto</LastName><ForeName>Pier Paolo</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Foundation for Biology and Regenerative Medicine, Tissue Engineering and Signaling - T.E.S. Onlus, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veronesi</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Complex Operative Unit of Transfusion Medicine - Marca Trevigiana Local Unit of Health and Social Services 2, Treviso Hospital, Piazzale dell'Ospedale 1, 31100, Treviso, Italy. arianna.veronesi@aulss2.veneto.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porzionato</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Human Anatomy, Department of Neuroscience, University of Padova, Via Gabelli 65, 35121, Padova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Foundation for Biology and Regenerative Medicine, Tissue Engineering and Signaling - T.E.S. Onlus, Padova, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Commun Signal</MedlineTA><NlmUniqueID>101170464</NlmUniqueID><ISSNLinking>1478-811X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="Y">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="Y">Single-Cell Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095028" MajorTopicYN="N">Multiomics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BD Rhapsody system</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Innate immune response</Keyword><Keyword MajorTopicYN="N">Natural killer lymphocytes</Keyword><Keyword MajorTopicYN="N">Single-cell multi-omics analysis</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>23</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407208</ArticleId><ArticleId IdType="pmc">PMC11476714</ArticleId><ArticleId IdType="doi">10.1186/s12964-024-01867-5</ArticleId><ArticleId IdType="pii">10.1186/s12964-024-01867-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Deng X, Terunuma H, Nieda M. Exploring the utility of NK cells in COVID-19. Biomedicines. 2022;10(5):1002. 10.3390/biomedicines10051002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9138257</ArticleId><ArticleId IdType="pubmed">35625739</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–4. 10.1016/S1473-3099(20)30120-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli G, Biancolella M, Mehrian-Shai R, Erickson C, Godri Pollitt KJ, Vasiliou V, Watt J, Reichardt JKV. COVID-19 update: the first 6 months of the pandemic. Hum Genomics. 2020;14(1):48. 10.1186/s40246-020-00298-w.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7757844</ArticleId><ArticleId IdType="pubmed">33357238</ArticleId></ArticleIdList></Reference><Reference><Citation>Unterman A, Sumida TS, Nouri N, Yan X, Zhao AY, Gasque V, Schupp JC, Asashima H, Liu Y, Cosme C Jr, Deng W, Chen M, Raredon MSB, Hoehn KB, Wang G, Wang Z, DeIuliis G, Ravindra NG, Li N, Castaldi C, Wong P, Fournier J, Bermejo S, Sharma L, Casanovas-Massana A, Vogels CBF, Wyllie AL, Grubaugh ND, Melillo A, Meng H, Stein Y, Minasyan M, Mohanty S, Ruff WE, Cohen I, Raddassi K, Yale IMPACTR, Team, Niklason LE, Ko AI, Montgomery RR, Farhadian SF, Iwasaki A, Shaw AC, van Dijk D, Zhao H, Kleinstein SH, Hafler DA, Kaminski N, Dela Cruz CS. Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nat Commun. 2022;13(1):440. 10.1038/s41467-021-27716-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782894</ArticleId><ArticleId IdType="pubmed">35064122</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrabadi ME, Hemmati R, Tashakor A, Homaei A, Yousefzadeh M, Hemati K, Hosseinkhani S. Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity. Biomed Pharmacother. 2021;137:111363. 10.1016/j.biopha.2021.111363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7862910</ArticleId><ArticleId IdType="pubmed">33582450</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, Chen Y, Zhang Y. COVID-19: immunopathogenesis and immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):128. 10.1038/s41392-020-00243-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381863</ArticleId><ArticleId IdType="pubmed">32712629</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, Strunz B, Lentini A, Reinius B, Brownlie D, Cuapio A, Ask EH, Hull RM, Haroun-Izquierdo A, Schaffer M, Klingström J, Folkesson E, Buggert M, Sandberg JK, Eriksson LI, Rooyackers O, Ljunggren HG, Malmberg KJ, Michaëlsson J, Marquardt N, Hammer Q, Strålin K, Björkström NK, Karolinska COVID-19 Study Group. Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. 2020;5(50):eabd6832. 10.1126/sciimmunol.abd6832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665314</ArticleId><ArticleId IdType="pubmed">32826343</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiuma G, Beltrami S, Bortolotti D, Rizzo S, Rizzo R. Innate Immune response in SARS-CoV-2 infection. Microorganisms. 2022;10(3):501. 10.3390/microorganisms10030501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8950297</ArticleId><ArticleId IdType="pubmed">35336077</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-2. Nat Immunol. 2022;23(2):165–76. 10.1038/s41590-021-01091-0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935980</ArticleId><ArticleId IdType="pubmed">35105981</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce S, Geanes ES, Bradley T. Targeting natural killer cells for Improved Immunity and Control of the adaptive Immune response. Front Cell Infect Microbiol. 2020;10:231. 10.3389/fcimb.2020.00231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7248265</ArticleId><ArticleId IdType="pubmed">32509600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministero della Salute - Consiglio Superiore di Sanità. Sessione LII Gruppo Di Lavoro. Quesiti Scientifici relativi all’infezione da Coronavirus SARS CoV-2: documento relativo alla definizione di Paziente Guarito Da COVID-19 e di Paziente Che ha eliminato Il virus SARS-CoV-2. Roma: Ministero della Salute; 2020 Feb 28.</Citation></Reference><Reference><Citation>Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, Hao Y, Stoeckius M, Smibert P, Satija R. Comprehensive Integration of Single-Cell Data. Cell. 2019;177(7):1888–e190221. 10.1016/j.cell.2019.05.031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Siebert JR, Burns R, Gerbec ZJ, Bonacci B, Rymaszewski A, Rau M, Riese MJ, Rao S, Carlson KS, Routes JM, Verbsky JW, Thakar MS, Malarkannan S. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat Commun. 2019;10(1):3931. 10.1038/s41467-019-11947-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6718415</ArticleId><ArticleId IdType="pubmed">31477722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi A, Trombetta E, Cattaneo A, Castelli V, Palomba E, Tirone M, Mangioni D, Lamorte G, Manunta M, Prati D, Ceriotti F, Gualtierotti R, Costantino G, Aliberti S, Scaravilli V, Grasselli G, Gori A, Porretti L, Bandera A. Early phases of COVID-19 are characterized by a reduction in lymphocyte populations and the Presence of atypical monocytes. Front Immunol. 2020;11:560330. 10.3389/fimmu.2020.560330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7756112</ArticleId><ArticleId IdType="pubmed">33362757</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martínez-Colón GJ, McKechnie JL, Ivison GT, Ranganath T, Vergara R, Hollis T, Simpson LJ, Grant P, Subramanian A, Rogers AJ, Blish CA. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26(7):1070–6. 10.1038/s41591-020-0944-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, Liu X, Xie L, Li J, Ye J, Dong L, Cui X, Miao Y, Wang D, Dong J, Xiao C, Chen W, Wang H. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 2020;6:31. 10.1038/s41421-020-0168-9. Erratum in: Cell Discov. 2020; 6:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197635</ArticleId><ArticleId IdType="pubmed">32377375</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfrini N, Notarbartolo S, Grifantini R, Pesce E. SARS-CoV-2: a glance at the Innate Immune Response elicited by infection and vaccination. Antibodies (Basel). 2024;13(1):13. 10.3390/antib13010013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10885122</ArticleId><ArticleId IdType="pubmed">38390874</ArticleId></ArticleIdList></Reference><Reference><Citation>Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H, Sabzevari A, Azizi G. Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2021;93(4):e12998. 10.1111/sji.12998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744910</ArticleId><ArticleId IdType="pubmed">33190302</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov S, Taskov H, Murdjeva M. Guardians of immunity: NK cell-mediated defense in COVID-19 and post-COVID scenarios. Folia Med (Plovdiv). 2024;66(1):12–18. 10.3897/folmed.66.e113356. PMID: 38426460.</Citation><ArticleIdList><ArticleId IdType="pubmed">38426460</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk AJ, Lee MJ, Wei B, Parks B, Pi R, Martínez-Colón GJ, Ranganath T, Zhao NQ, Taylor S, Becker W, Stanford D, Blomkalns AL, O’Hara R, Ashley EA, Nadeau KC, Yang S, Holmes S, Rabinovitch M, Rogers AJ, Greenleaf WJ, Blish CA. Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. J Exp Med. 2021; 218(8):e20210582. 10.1084/jem.20210582</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8210586</ArticleId><ArticleId IdType="pubmed">34128959</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Abdel-Mohsen M, Henrich TJ, Roan NR. Systems analysis of innate and adaptive immunity in Long COVID. Semin Immunol. 2024;72:101873. 10.1016/j.smim.2024.101873.</Citation><ArticleIdList><ArticleId IdType="pubmed">38460395</ArticleId></ArticleIdList></Reference><Reference><Citation>Müller S, Schultze JL. Systems analysis of human innate immunity in COVID-19. Semin Immunol. 2023;68:101778. 10.1016/j.smim.2023.101778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10201327</ArticleId><ArticleId IdType="pubmed">37267758</ArticleId></ArticleIdList></Reference><Reference><Citation>Montaldo C, Messina F, Abbate I, Antonioli M, Bordoni V, Aiello A, Ciccosanti F, Colavita F, Farroni C, Najafi Fard S, Giombini E, Goletti D, Matusali G, Rozera G, Rueca M, Sacchi A, Piacentini M, Agrati C, Fimia GM, Capobianchi MR, Lauria FN, Ippolito G. Multi-omics approach to COVID-19: a domain-based literature review. J Transl Med. 2021;19(1):501. 10.1186/s12967-021-03168-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8649311</ArticleId><ArticleId IdType="pubmed">34876157</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni J, Chattopadhyay P, Mehta P, Mohite R, Tardalkar K, Joshi M, Pandey R. Dynamics of whole transcriptome analysis (WTA) and surface markers expression (AbSeq) in Immune cells of COVID-19 patients and recovered captured through single Cell Genomics. Front Med (Lausanne). 2024;11:1297001. 10.3389/fmed.2024.1297001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10864604</ArticleId><ArticleId IdType="pubmed">38357647</ArticleId></ArticleIdList></Reference><Reference><Citation>Vendramini E, Bomben R, Pozzo F, Bittolo T, Tissino E, Gattei V, Zucchetto A. KRAS and RAS-MAPK pathway deregulation in mature B Cell Lymphoproliferative disorders. Cancers (Basel). 2022;14(3):666. 10.3390/cancers14030666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8833570</ArticleId><ArticleId IdType="pubmed">35158933</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno H, Yamamoto T, Yamazaki K, Gohda J, Akiyama T, Semba K, Goto H, Kato A, Yujiri T, Imai T, Kawaguchi Y, Su B, Takeuchi O, Akira S, Tsunetsugu-Yokota Y, Inoue J. TRAF6 establishes innate immune responses by activating NF-kappaB and IRF7 upon sensing cytosolic viral RNA and DNA. PLoS ONE. 2009;4(5):e5674. 10.1371/journal.pone.0005674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682567</ArticleId><ArticleId IdType="pubmed">19479062</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiger TL, Sun JC. Development and maturation of natural killer cells. Curr Opin Immunol. 2016;39:82–9. 10.1016/j.coi.2016.01.007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4801705</ArticleId><ArticleId IdType="pubmed">26845614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Iizuka K, Kang HS, Dokun A, French AR, Greco S, Yokoyama WM. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol. 2002;3(6):523–8. 10.1038/ni796.</Citation><ArticleIdList><ArticleId IdType="pubmed">12006976</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 2007;7(9):703 – 14. 10.1038/nri2154. PMID: 17717540.</Citation><ArticleIdList><ArticleId IdType="pubmed">17717540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, Li Y, Zhang Z, Fu Y, Han X, Hu Q, Ding H, Shang H, Jiang Y. CD160 promotes NK Cell functions by Upregulating Glucose Metabolism and negatively correlates with HIV Disease Progression. Front Immunol. 2022;13:854432. 10.3389/fimmu.2022.854432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9469471</ArticleId><ArticleId IdType="pubmed">36110864</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JY, Wang XM, Xing X, Xu Z, Zhang C, Song JW, Fan X, Xia P, Fu JL, Wang SY, Xu RN, Dai XP, Shi L, Huang L, Jiang TJ, Shi M, Zhang Y, Zumla A, Maeurer M, Bai F, Wang FS. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020;21(9):1107–18. 10.1038/s41590-020-0762-x.</Citation><ArticleIdList><ArticleId IdType="pubmed">32788748</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mterin MA, Alsalman A, Elkord E. Inhibitory Immune checkpoint receptors and ligands as prognostic biomarkers in COVID-19 patients. Front Immunol. 2022;13:870283. 10.3389/fimmu.2022.870283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9008255</ArticleId><ArticleId IdType="pubmed">35432324</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy U, Martinelli R, Vollmann EH, Best K, Therien AG. The impact of DAMP-mediated inflammation in severe COVID-19 and related disorders. Biochem Pharmacol. 2022;195:114847. 10.1016/j.bcp.2021.114847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8600760</ArticleId><ArticleId IdType="pubmed">34801526</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan L, Fung TS, He J, Chen RA, Liu DX. Modulation of viral replication, apoptosis and antiviral response by induction and mutual regulation of EGR and AP-1 family genes during coronavirus infection. Emerg Microbes Infect. 2022;11(1):1717–29. 10.1080/22221751.2022.2093133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9262369</ArticleId><ArticleId IdType="pubmed">35727266</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoque MN, Sarkar MMH, Khan MA, Hossain MA, Hasan MI, Rahman MH, Habib MA, Akter S, Banu TA, Goswami B, Jahan I, Nafisa T, Molla MMA, Soliman ME, Araf Y, Khan MS, Zheng C, Islam T. Differential gene expression profiling reveals potential biomarkers and pharmacological compounds against SARS-CoV-2: insights from machine learning and bioinformatics approaches. Front Immunol. 2022;13:918692. 10.3389/fimmu.2022.918692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9429819</ArticleId><ArticleId IdType="pubmed">36059456</ArticleId></ArticleIdList></Reference><Reference><Citation>Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, Morandi B, Ferlazzo G, Thiel A, Schmitt-Knosalla I, Romagnani C. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood. 2010;116(8):1299–307. 10.1182/blood-2009-11-253286.</Citation><ArticleIdList><ArticleId IdType="pubmed">20505160</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnoegl D, Hiesinger A, Huntington ND, Gotthardt D. AP-1 transcription factors in cytotoxic lymphocyte development and antitumor immunity. Curr Opin Immunol. 2023;85:102397. 10.1016/j.coi.2023.102397.</Citation><ArticleIdList><ArticleId IdType="pubmed">37931499</ArticleId></ArticleIdList></Reference><Reference><Citation>Malengier-Devlies B, Filtjens J, Ahmadzadeh K, Boeckx B, Vandenhaute J, De Visscher A, Bernaerts E, Mitera T, Jacobs C, Vanderbeke L, Van Mol P, Van Herck Y, Hermans G, Meersseman P, Wilmer A, Gouwy M, Garg AD, Humblet-Baron S, De Smet F, Martinod K, Wauters E, Proost P, Wouters C, Leclercq G, Lambrechts D, Wauters J, Matthys P. Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates. Front Immunol. 2022;13:861251. 10.3389/fimmu.2022.861251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9581751</ArticleId><ArticleId IdType="pubmed">36275702</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani B, Najafizadeh M, Motedayyen H, Arefnezhad R. Predicting roles of IL-27 and IL-32 in determining the severity and outcome of COVID-19. Int J Immunopathol Pharmacol. 2022;36:3946320221145827. 10.1177/03946320221145827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9742516</ArticleId><ArticleId IdType="pubmed">36476070</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda M, Omatsu Y, Sugiyama T, Oishi S, Fujii N, Nagasawa T. CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice. Blood. 2011;117(2):451–8. 10.1182/blood-2010-04-277897.</Citation><ArticleIdList><ArticleId IdType="pubmed">20944068</ArticleId></ArticleIdList></Reference><Reference><Citation>Basílio-Queirós D, Mischak-Weissinger E. Natural killer cells- from innate cells to the discovery of adaptability. Front Immunol. 2023;14:1172437. 10.3389/fimmu.2023.1172437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10232812</ArticleId><ArticleId IdType="pubmed">37275911</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer Q, Rückert T, Borst EM, Dunst J, Haubner A, Durek P, Heinrich F, Gasparoni G, Babic M, Tomic A, Pietra G, Nienen M, Blau IW, Hofmann J, Na IK, Prinz I, Koenecke C, Hemmati P, Babel N, Arnold R, Walter J, Thurley K, Mashreghi MF, Messerle M, Romagnani C. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat Immunol. 2018;19(5):453–63. 10.1038/s41590-018-0082-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29632329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ustiuzhanina MO, Vavilova JD, Boyko AA, Streltsova MA, Kust SA, Kanevskiy LM, Sapozhnikov AM, Iskhakov RN, Gubernatorova EO, Drutskaya MS, Bychinin MV, Zhukova OA, Novikova ON, Sotnikova AG, Yusubalieva GM, Baklaushev VP, Kovalenko EI. Coordinated loss and Acquisition of NK cell surface markers accompanied by generalized Cytokine Dysregulation in COVID-19. Int J Mol Sci. 2023;24(3):1996. 10.3390/ijms24031996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9917026</ArticleId><ArticleId IdType="pubmed">36768315</ArticleId></ArticleIdList></Reference><Reference><Citation>Vietzen H, Zoufaly A, Traugott M, Aberle J, Aberle SW, Puchhammer-Stöckl E. Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19. Genet Med. 2021;23(5):963–7. 10.1038/s41436-020-01077-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7835668</ArticleId><ArticleId IdType="pubmed">33500568</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox A, Cevik H, Feldman HA, Canaday LM, Lakes N, Waggoner SN. Targeting natural killer cells to enhance vaccine responses. Trends Pharmacol Sci. 2021;42(9):789–801. 10.1016/j.tips.2021.06.004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8364504</ArticleId><ArticleId IdType="pubmed">34311992</ArticleId></ArticleIdList></Reference><Reference><Citation>Luetke-Eversloh M, Killig M, Romagnani C. Signatures of human NK cell development and terminal differentiation. Front Immunol. 2013;4:499. 10.3389/fimmu.2013.00499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3874559</ArticleId><ArticleId IdType="pubmed">24416035</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen CM, White MJ, Goodier MR, Riley EM. Functional significance of CD57 expression on Human NK cells and relevance to Disease. Front Immunol. 2013;4:422. 10.3389/fimmu.2013.00422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3856678</ArticleId><ArticleId IdType="pubmed">24367364</ArticleId></ArticleIdList></Reference><Reference><Citation>Savchenko AA, Kudryavtsev IV, Isakov DV, Sadowski IS, Belenyuk VD, Borisov AG. Recombinant human Interleukin-2 corrects NK Cell phenotype and functional activity in patients with Post-COVID syndrome. Pharmaceuticals (Basel). 2023;16(4):537. 10.3390/ph16040537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10144656</ArticleId><ArticleId IdType="pubmed">37111294</ArticleId></ArticleIdList></Reference><Reference><Citation>White MJ, Nielsen CM, McGregor RH, Riley EH, Goodier MR. Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens. Immunology. 2014;142(1):140–50. 10.1111/imm.12239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992055</ArticleId><ArticleId IdType="pubmed">24843874</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Vito C, Calcaterra F, Coianiz N, Terzoli S, Voza A, Mikulak J, Della Bella S, Mavilio D. Natural killer cells in SARS-CoV-2 infection: pathophysiology and therapeutic implications. Front Immunol. 2022;13:888248. 10.3389/fimmu.2022.888248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279859</ArticleId><ArticleId IdType="pubmed">35844604</ArticleId></ArticleIdList></Reference><Reference><Citation>Scourfield DO, Reed SG, Quastel M, Alderson J, Bart VMT, Teijeira Crespo A, Jones R, Pring E, Richter FC, Oxford-Cardiff, COVID-19 Literature Consortium, Burnell SEA. The role and uses of antibodies in COVID-19 infections: a living review. Oxf Open Immunol. 2021;2(1):iqab003. 10.1093/oxfimm/iqab003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928637</ArticleId><ArticleId IdType="pubmed">34192270</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajissa K, Mussa A, Karobari MI, Abbas MA, Ibrahim IK, Assiry AA, Iqbal A, Alhumaid S, Mutair AA, Rabaan AA, Messina P, Scardina GA. The SARS-CoV-2 antibodies, their diagnostic utility, and their potential for Vaccine Development. Vaccines (Basel). 2022;10(8):1346. 10.3390/vaccines10081346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9412318</ArticleId><ArticleId IdType="pubmed">36016233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–e2808. 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, De Angelis ML, Baratella M, Bazzigaluppi E, Venturi G, Sironi F, Canitano A, Marzinotto I, Tresoldi C, Ciceri F, Piemonti L, Negri D, Cara A, Lampasona V, Scarlatti G. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun. 2021;12(1):2670. 10.1038/s41467-021-22958-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113594</ArticleId><ArticleId IdType="pubmed">33976165</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 2020;16(10):1718–23. 10.7150/ijbs.45123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7098029</ArticleId><ArticleId IdType="pubmed">32226289</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490–6. 10.1073/pnas.2004168117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196837</ArticleId><ArticleId IdType="pubmed">32253318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020;92(10):1890–901. 10.1002/jmv.25882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262027</ArticleId><ArticleId IdType="pubmed">32293713</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol. 2020;92(9):1475–83. 10.1002/jmv.25961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267113</ArticleId><ArticleId IdType="pubmed">32356910</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, Eubank T, Bernard DW, Eagar TN, Long SW, Subedi S, Olsen RJ, Leveque C, Schwartz MR, Dey M, Chavez-East C, Rogers J, Shehabeldin A, Joseph D, Williams G, Thomas K, Masud F, Talley C, Dlouhy KG, Lopez BV, Hampton C, Lavinder J, Gollihar JD, Maranhao AC, Ippolito GC, Saavedra MO, Cantu CC, Yerramilli P, Pruitt L, Musser JM. Treatment of Coronavirus Disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol. 2020;190(8):1680–90. 10.1016/j.ajpath.2020.05.014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251400</ArticleId><ArticleId IdType="pubmed">32473109</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475–84. 10.1038/s41577-021-00578-z.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8246128</ArticleId><ArticleId IdType="pubmed">34211186</ArticleId></ArticleIdList></Reference><Reference><Citation>Arter C, Trask L, Ward S, Yeoh S, Bayliss R. Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors. J Biol Chem. 2022;298(8):102247. 10.1016/j.jbc.2022.102247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9382423</ArticleId><ArticleId IdType="pubmed">35830914</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik RR, Shakya AK, Aladwan SM, El-Tanani M. Kinase inhibitors as potential therapeutic agents in the treatment of COVID-19. Front Pharmacol. 2022;13:806568. 10.3389/fphar.2022.806568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014181</ArticleId><ArticleId IdType="pubmed">35444538</ArticleId></ArticleIdList></Reference><Reference><Citation>Žarković N, Łuczaj W, Jarocka-Karpowicz I, Orehovec B, Baršić B, Tarle M, Kmet M, Lukšić I, Biernacki M, Skrzydlewska E. Diversified effects of COVID-19 as a consequence of the Differential metabolism of phospholipids and lipid peroxidation evaluated in the plasma of survivors and deceased patients upon admission to the hospital. Int J Mol Sci. 2022;23(19):11810. 10.3390/ijms231911810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9570244</ArticleId><ArticleId IdType="pubmed">36233111</ArticleId></ArticleIdList></Reference><Reference><Citation>Fé LXSGM, Cipolatti EP, Pinto MCC, Branco S, Nogueira FCS, Ortiz GMD, Pinheiro AS, Manoel EA. Enzymes in the time of COVID-19: an overview about the effects in the human body, enzyme market, and perspectives for new drugs. Med Res Rev. 2022;42(6):2126–67. 10.1002/med.21919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350392</ArticleId><ArticleId IdType="pubmed">35762498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic Injury patterns in patients with Coronavirus Disease 19 Pneumonia. Gastroenterology. 2020;159(1):367–70. 10.1053/j.gastro.2020.03.055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118654</ArticleId><ArticleId IdType="pubmed">32247022</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlass U, Wiliams B, Dhana K, Adnan D, Khan SR, Mahdavinia M, Bishehsari F. Marked elevation of lipase in COVID-19 Disease: a Cohort Study. Clin Transl Gastroenterol. 2020;11(7):e00215. 10.14309/ctg.0000000000000215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386395</ArticleId><ArticleId IdType="pubmed">32764201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyak M, Düzenli T. Lipase elevation on admission predicts worse clinical outcomes in patients with COVID-19. Pancreatology. 2022;22(5):665–70. 10.1016/j.pan.2022.04.012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9054729</ArticleId><ArticleId IdType="pubmed">35537935</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek YB, Kwon HJ, Sharif M, Lim J, Lee IC, Ryu YB, Lee JI, Kim JS, Lee YS, Kim DH, Park SI, Kim DK, Kim JS, Choy HE, Lee S, Choi HS, Osborne TF, Jeon TI, Cho KO. Therapeutic strategy targeting host lipolysis limits infection by SARS-CoV-2 and influenza a virus. Signal Transduct Target Ther. 2022;7(1):367. 10.1038/s41392-022-01223-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9575645</ArticleId><ArticleId IdType="pubmed">36253361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>